TuisRLF • SWX
add
RELIEF THERAPEUTICS Holding SA
Vorige sluiting
CHF 2,88
Dagwisseling
CHF 2,79 - CHF 2,88
Jaarwisseling
CHF 1,65 - CHF 7,60
Markkapitalisasie
40,56 m CHF
Gemiddelde volume
20,74 k
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
SWX
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (CHF) | Jun. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 609,00 k | -78,18% |
Bedryfskoste | 2,57 m | -35,75% |
Netto inkomste | -2,24 m | 1,73% |
Netto winsgrens | -367,65 | -350,28% |
Wins per aandeel | — | — |
EBITDA | -2,01 m | -42,73% |
Effektiewe belastingkoers | 0,58% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (CHF) | Jun. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 12,50 m | — |
Totale bates | 47,99 m | — |
Totale aanspreeklikheid | 15,35 m | — |
Totale ekwiteit | 32,63 m | — |
Uitstaande aandele | 12,58 m | — |
Prys om te bespreek | 1,11 | — |
Opbrengs op bates | -11,77% | — |
Opbrengs op kapitaal | -16,36% | — |
Kontantvloei
Netto kontantverandering
| (CHF) | Jun. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | -2,24 m | 1,73% |
Kontant van bedrywe | -1,88 m | -18,76% |
Kontant van beleggings | 644,00 k | 18 500,00% |
Kontant van finansiering | -28,50 k | 90,75% |
Netto kontantverandering | -1,29 m | 32,60% |
Beskikbare kontantvloei | -284,81 k | — |
Meer oor
Relief Therapeutics is a Swiss biopharmaceutical company based in Geneva. The company focuses on developing drugs for serious diseases with few or no existing treatment options. Its lead compound, RLF-100, is a synthetic form of a natural peptide that protects the lung. The company was incorporated as Relief Therapeutics Holdings AG and listed on the SIX Swiss Exchange in 2016. Wikipedia
Gestig
2013
Webwerf
Werknemers
28
